Literature DB >> 2581392

Rat alpha 1 macroglobulin inhibits hemagglutination by influenza C virus.

G Herrler, R Geyer, H P Müller, S Stirm, H D Klenk.   

Abstract

Purified alpha 1-macroglobulin (RMG) isolated from rat plasma was found to be a potent inhibitor of hemagglutination by influenza C virus. Neuraminidase treatment of purified RMG reduced its inhibitory activity by more than 80% indicating that sialic acid is required for maximal HI-activity. The inhibitory activity of RMG was shown to be sensitive to the receptor-destroying activity (RDA) of influenza C virus. Methylation analysis of the glycopeptides of RMG indicated the presence of only one major type of oligosaccharide which is a complex N-linked oligosaccharide with a biantennary structure. Comparison of the glycopeptides before and after neuraminidase treatment revealed that the oligosaccharides are terminated by sialic acid residues attached to galactose residues at position C-6. Methylation analysis was also performed on RMG which had lost its inhibitory activity upon incubation with RDA of influenza C virus. No difference between the glycopeptides of native and inactive RMG could be detected. Galactose was found to be substituted at position C-6 in both samples, indicating that also the oligosaccharides of inactive RMG are terminated by sialic acid. The implications of these results are discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2581392     DOI: 10.1016/0168-1702(85)90248-5

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  10 in total

1.  Identification of a coronavirus hemagglutinin-esterase with a substrate specificity different from those of influenza C virus and bovine coronavirus.

Authors:  A Klausegger; B Strobl; G Regl; A Kaser; W Luytjes; R Vlasak
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  The S protein of bovine coronavirus is a hemagglutinin recognizing 9-O-acetylated sialic acid as a receptor determinant.

Authors:  B Schultze; H J Gross; R Brossmer; G Herrler
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

3.  Acetylated galactosamine is a receptor for the influenza C virus glycoprotein.

Authors:  P Luther; W Cushley; C Hölzer; U Desselberger; J S Oxford
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

4.  Serine 71 of the glycoprotein HEF is located at the active site of the acetylesterase of influenza C virus.

Authors:  G Herrler; G Multhaup; K Beyreuther; H D Klenk
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

5.  Hemagglutinating encephalomyelitis virus attaches to N-acetyl-9-O-acetylneuraminic acid-containing receptors on erythrocytes: comparison with bovine coronavirus and influenza C virus.

Authors:  B Schultze; H J Gross; R Brossmer; H D Klenk; G Herrler
Journal:  Virus Res       Date:  1990-06       Impact factor: 3.303

6.  A single point mutation of the influenza C virus glycoprotein (HEF) changes the viral receptor-binding activity.

Authors:  S Szepanski; H J Gross; R Brossmer; H D Klenk; G Herrler
Journal:  Virology       Date:  1992-05       Impact factor: 3.616

7.  The receptor-destroying enzyme of influenza C virus is neuraminate-O-acetylesterase.

Authors:  G Herrler; R Rott; H D Klenk; H P Müller; A K Shukla; R Schauer
Journal:  EMBO J       Date:  1985-06       Impact factor: 11.598

8.  Isolated HE-protein from hemagglutinating encephalomyelitis virus and bovine coronavirus has receptor-destroying and receptor-binding activity.

Authors:  B Schultze; K Wahn; H D Klenk; G Herrler
Journal:  Virology       Date:  1991-01       Impact factor: 3.616

Review 9.  Structure and function of the HEF glycoprotein of influenza C virus.

Authors:  G Herrler; H D Klenk
Journal:  Adv Virus Res       Date:  1991       Impact factor: 9.937

Review 10.  Host Range, Biology, and Species Specificity of Seven-Segmented Influenza Viruses-A Comparative Review on Influenza C and D.

Authors:  Chithra C Sreenivasan; Zizhang Sheng; Dan Wang; Feng Li
Journal:  Pathogens       Date:  2021-12-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.